Evidence Table 159. KQ3—Dichotomous—Withdrawal due to adverse events

| **Author Year****Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug****(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Bays20106Parallel | N/A | Unclear | Atorvastatin (10-40) | Omega-3 | 123 | 8 | Placebo | 122 | 6 |  |  | Medium |
| Ferraro200922Parallel | N/A | Unclear | Ramipril (10) | Omega-3 | 15 | 0 | No Treatment | 15 | 0 |  |  | Medium |
| Mabuchi200739Parallel | N/A | Unclear | Atorvastatin (10) | Co-Q10 |  |  | Placebo |  |  |  | "There were no serious adverse events". Data not reported. | Medium |
| Gardner200723Parallel | N/A | Mixed: Moderate to high | ASA (325) | Ginkgo biloba |  | 3 | Placebo |  | 2 |  |  | Low |
| Young200770Parallel | N/A | Mixed:Moderate and high risk | Simvastatin (10 - 40) | Co-Q10 |  | 6 | Placebo |  | 4 |  |  | Medium |
| Davidson200714Parallel | N/A | Unclear | Simvastatin (40) | Omega-3 | 122 | 3 | Placebo | 132 | 3 |  | no description | Medium |
| D’Arcangues200413Parallel | discontinuation due to side effects of treatment | Mixed: Low and/or Moderate | ASA (80) | Vitamin E | 121 | 30 | No Treatment | 122 | 19 |  | Treatment course was for 10 days. But followup went on for up to 1 year. | Medium |
| Nordøy200054Parallel | N/A | Mixed: Low and/or Moderate | Simvastatin (20) | Omega-3 | 21 | 0 | Placebo | 20 | 0 |  |  | Medium |
| Garg199524Parallel | N/A | At high risk for CHD | ASA and/or pentoxiphylline (20) | Ginkgo biloba | 29 | 0 | Placebo | 26 | 0 |  |  | Medium-high |
| Paolissa199257Parallel | N/A | Unclear | Hydrochlorthiazide (25) | Magnesium | 9 | 0 | Placebo | 9 | 0 |  |  | Medium |
| Kaul199234Parallel | GI intolerance-- stopped capsules of fish oil | At high risk for CHD | Calcium channel blocker, ASA (NR) | Omega-3 | 58 | 2 | No Treatment | 49 | 0 |  |  | Low-medium |

Evidence Table 159. KQ3—Dichotomous—Withdrawal due to adverse events (continued)

| **Author Year****Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug****(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Nordøy200355Parallel | N/A | Mixed: Moderate and high risk | Atorvastatin (10) | Omega-3 | 22 | 0 | Placebo | 20 | 0 |  |  | Low  |
| Roth200960Parallel | N/A | Unclear | Fenofibrate (130) | Omega-3 | 84 | 4 | Placebo | 83 | 4 |  |  | Medium |
| Isley200731Parallel | N/A | Unclear | Niacin (500); ASA (325) | Omega-3 | 8 |  | No Treatment | 7 |  |  |  | Medium |
| Bender19988Parallel | N/A | Unclear | Warfarin ( NR) | Omega-3 | 6 | 0 | No Treatment | 5 | 0 |  |  | High |
| Chan200212Parallel | N/A | At moderate/moderately high risk for CHD (2+ risk factors) | Atorvastatin (40) | Omega-3 | 11 | 0 | No Treatment | 13 | 0 |  |  | Medium |
| Playford200358Parallel | N/A | At high risk for CHD | Fenofibrate (200) | Co-Q10 | 18 |  | No Treatment | 17 |  |  |  | Low-medium |
| Abdul20101Crossover | N/A | At low risk for CHD (0-1 risk factors) | Warfarin (25 single dose) | Echinacea | 12 | 0 | No Treatment | 12 | 0 |  |  | Medium |
| Gosai200826Crossover | N/A | At low risk for CHD (0-1 risk factors) | Rosuvastatin (40) | Omega-3 | 48 | 2 | No Treatment | 48 | 4 |  |  | Medium |
| Di Spirito200819Crossover | N/A | At low risk for CHD (0-1 risk factors) | Atorvastatin (80) | Omega-3 | 50 | 1 | No Treatment | 50 | 0 |  | This one is the same patient who had an elevated CK | Medium |
| Maki200841Crossover | N/A | Mixed:Low, Moderate and high risk | Simvastatin (20) | Omega-3 |  | 2 | Placebo |  | 1 |  |  | Medium |
| McKenney200645Crossover | N/A | Mixed:Low and/or Moderate | Simvastatin (80) | Omega-3 | 24 | 1 | No Treatment | 24 | 0 |  |  | Medium |

Evidence Table 159. KQ3—Dichotomous—Withdrawal due to adverse events (continued)

| **Author Year****Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug****(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Jiang200532Crossover | N/A | At low risk for CHD (0-1 risk factors) | Warfarin (25 single dose) | Gingko biloba |  | 0 | No Treatment |  | 0 |  |  | Medium |
| Jiang 200433Crossover | N/A | At low risk for CHD (0-1 risk factors) | Warfarin (25 single dose) | Ginseng |  | 0 | No Treatment |  | 0 |  |  | Medium |
| Mauro200343Crossover | N/A | At low risk for CHD (0-1 risk factors) | Digoxin (0.5 single dose) | Gingko biloba |  | 0 | No Treatment |  | 0 |  |  | Medium |
| Balestrieri19964Crossover | N/A | Mixed:Low and/or mod to high risk | Simvastatin (10 to 40) | Omega-3 | 16 | 1 | Placebo | 16 | 1 |  | Two patients (one in each group) interrupted the study in the first month. One suffered from acute myocardial infarction, another one underwent a resection of abdominal aortic aneurysm. | Medium |
| Paolissa199256Crossover | N/A | At high risk for CHD | Nifedipine (88) | Vitamin E |  | 0 | Placebo |  | 0 |  |  | Medium |
| Mueller199151Crossover | N/A | Mixed:Low and/or Moderate | ASA (325 single dose) | Omega-3 |  | 0 | Placebo |  | 0 |  |  | Medium |
| Wirell199467Crossover | N/A | Unclear | metoprolol, atenolol, pindolol & propanolol (NR) | Magnesium | 19 |  | Placebo | 20 | 0 |  |  | Medium |
| Avogaro19743Crossover | N/A | Unclear | Propranolol (20 or 60) | Niacin | 10 | 0 | No Treatment | 10 | 1 |  |  | High |